Please ensure Javascript is enabled for purposes of website accessibility

Why Sangamo Therapeutics Stock Soared 27% in January

By Demitri Kalogeropoulos - Feb 8, 2018 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors rewarded this gene editing specialist for advancing its treatments deeper into clinical trials.

What happened

Gene therapy specialist Sangamo Therapeutics (SGMO 3.38%) trounced the market in January, jumping 27% compared to a 6% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.

The surge helped the stock approach the all-time high that shareholders last saw in early 2014. Sangamo has risen more than 400% in just the past 52 weeks.

^SPX Chart

^SPX data by YCharts

So what

Investors sent shares higher last month following a presentation by management that detailed several promising drug and treatment products it was working on, including one gene editing approach to battle HIV and another aimed at eradicating a metabolic disease called Hunter syndrome.

Two clinical researchers at work using a microscope.

Image source: Getty Images.

Now what

Less than a month later, Sangamo added to the optimism by revealing progress in its current test of the Hunter syndrome treatment in two patients. That constitutes the first clinical trial of gene editing therapies in the United States, and so far the infusions have gone well, doctors said, with "no concerning safety issues" coming up.

It's impossible to quantify the value of this early stage research, but investors have been rewarding Sangamo for having the most advanced pipeline in this potentially game-changing arena of medical research.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sangamo Therapeutics Stock Quote
Sangamo Therapeutics
SGMO
$4.28 (3.38%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.